SEARCH

Entries in Bladder Cancer (1)

Friday
Sep242010

FDA Looks Into Diabetes Drug 'Actos' For Risk Of Cancer

Photo Courtesy -- ABC News(NEW YORK) -- According to reports by WebMD, The FDA has launched a safety review of the diabetes drug Actos in light of new data suggesting that the drug may increase risk of bladder cancer.  While not considered a serious enough risk to prevent FDA approval, earlier animal and human studies linked Actos to bladder cancer.  As a condition of approval, the FDA insisted that Actos maker Takeda Pharmaceuticals look for bladder cancer in patients taking the drug.  Now five years in to Takeda's 10-year study, the overall data is reassuring.  WebMD urges patients taking Actos that they do not have an increased risk of bladder cancer.  However, when researchers looked only at patients who had taken Actos the longest, and who had accumulated the highest lifetime dose of the drug, they found risk emerged in patients who had taken Actos for at least 24 months.  The FDA stresses that the finding is not proof that Actos causes bladder cancer. WebMD warned that Patients who are taking Actos are advised not to stop taking their medication unless advised to do so by their health care provider.  Concerned patients should discuss the new information with their doctors.  Actos is widely considered to be safer than Avandia, the only other approved diabetes drug in its class. The FDA is currently considering whether Avandia should remain on the market. An FDA expert advisory panel recently split over the issue.

Copyright 2010 ABC News Radio

 







ABC News Radio